Drug Information
| Drug General Information | |||||
|---|---|---|---|---|---|
| Drug ID |
D07UKF
|
||||
| Former ID |
DIB001168
|
||||
| Drug Name |
VBY-129
|
||||
| Synonyms |
Cathepsin S inhibitor (oral, psoriasis), Virobay
|
||||
| Indication | Autoimmune diabetes [ICD10:E08-E13] | Phase 1 | [1] | ||
| Company |
Virobay Inc
|
||||
| Target and Pathway | |||||
| Target(s) | Cathepsin S | Target Info | Inhibitor | [2] | |
| KEGG Pathway | Lysosome | ||||
| Phagosome | |||||
| Antigen processing and presentation | |||||
| Tuberculosis | |||||
| NetPath Pathway | Leptin Signaling Pathway | ||||
| IL2 Signaling Pathway | |||||
| Reactome | Endosomal/Vacuolar pathway | ||||
| Degradation of the extracellular matrix | |||||
| Trafficking and processing of endosomal TLR | |||||
| Assembly of collagen fibrils and other multimeric structures | |||||
| MHC class II antigen presentation | |||||
| WikiPathways | Class I MHC mediated antigen processing & presentation | ||||
| Trafficking and processing of endosomal TLR | |||||
| References | |||||
| REF 1 | Clinical pipeline report, company report or official report of ViroBay. | ||||
| REF 2 | Clinical pipeline report, company report or official report of ViroBay. | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.